1Dixon JM,Anderson TJ,Miller WR.Neoadjuvant endocrine therapy of breast cancer:a surgical perspective[J].Eur J Cancer,2002,38(17) 2214-2221.
2Ellis MJ,CoopA,SinghB,et al.Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive,estrogen receptor-positive primary breast cancer:evidence from phase Ⅲ randomized trial[J].J Clin Oncol,2001,199(18):3808-3816.
3Early Breast Cancer Trialist,s Collaborative Group(EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomized trials[J].Lancet,2005,365(9472):1687-1717.
4Fisher B,Dignam etal.Five versus more than five years of tamoxifen for lymph node-negtive breast cancer:Update fingdings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial[J].J Natl.Cancer Inst,2001.93:684-690.
5Bolufel P,Ricart E,IJuch A,el al.Aromatase activity and estradiol in human breast cancer:its relationship to estradiol mad epidermal growth factor receptors and to tumor-node-metastasis staging[J].J Clin Oncol,1992.10:438-446.
6Mouridsen H.Gershanovich M.Sun Y,el al.Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:results of a phase III study of the International Letrozole Breast Cancer Group[J].J Clin Oneol,2001,19:2596-2606.
7Nabholtz JM,Buzdal A,Pollak M,et al.Anastrozole is superior to tamoxifen as first-1ine therapy for advanced breast cancer in postmenopausal women:results of a North American multicenter randomized tria1[J].Arimidex Study Group.J Clin Oncol,2000,18:3758-3767.
9Eiermann W,Paepke S,Appfelstaedt J,et al.Preoperative treatment of postmenopausal breast cancer patients with letrozole:a randomized double-blind multicenter study[J].Ann Oncol,2001,12(11):1527-1532.
10Dixon JM,Love CD,Bellamy CO,et al.Letrozole as primary medical therapy for locally advanced and large operable breast cancer[J].Breast Cancer Res Treat,2001,66(3):191-199.
5W. Eiermann,S. Paepke,J. Appfelstaedt,A. Llombart-Cussac,J. Eremin,J. Vinholes,L. Mauriac,M. Ellis,M. Lassus,H. A. Chaudri-Ross,M. Dugan,M. Borgs,V. Semiglazov. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study[J] 2001,Annals of Oncology(11):1527～1532
8Bolufer P,Ricart E,Lluch A,et al.Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging[].Journal of Clinical Oncology.1992
9Mouridsen H,Gershanovich M,Sun Y,et al.Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the international letrozole breast cancer group[].Journal of Clinical Oncology.2001
10Nabholtz JM,Buzdar A,Pollak M,et al.Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial.Arimidex Study Group[].Journal of Clinical Oncology.2000
2Therasse P, Arbuek SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Nal Cancer Inst,2000,92 ( 1 ) :205-216.
3Ellis M J, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res,2003,63 (19) :6523-6524.
4Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal-women with advanced breast cancer : results of a phase Ⅲ study of the international letrozole breast cancer group. Clin Oncol,2001, 19(10) :2596-2606.
